7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial

Table 2 Treatment characteristics among critically ill patients with bacteremia

Treatment characteristics^a	N (%), Median (IQR)
Empiric antimicrobial treatment^b
Number of unique empiric antimicrobials administered	2 (2–3)
Number of unique adequate^d empiric antimicrobials administered	2 (1–2)
Overall antimicrobial treatments^c
Number of unique antimicrobials administered	3 (3–5)
Number of unique adequate^d antimicrobials administered	3 (2–3)
Top 10 most commonly administered antimicrobials
Piperacillin-tazobactam	85 (73.9%)
Vancomycin	65 (56.5%)
Ceftriaxone	58 (50.4%)
Ciprofloxacin	42 (36.5%)
Meropenem	35 (30.4%)
Metronidazole	22 (19.1%)
Cefazolin	20 (17.4%)
Ampicillin	19 (16.5%)
Tobramycin	14 (12.2%)
Amoxicillin-clavulanate	11 (9.6%)
Underwent a source control procedure	76 (66.1%)

^aAll data are presented as medians and interquartile ranges (IQR) unless otherwise specified
^bEmpiric treatment window defined as period between blood culture collection and finalization
^cOverall treatments received within 30 days after blood culture collection
^dAdequate antimicrobials defined by in vitro activity against the blood culture pathogen(s)

ISSN: 1745-6215